{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:11Z","timestamp":1746417731822,"version":"3.40.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Golimumab is a fully human antitumor necrosis monoclonal antibody that can be administered by either subcutaneous injection or intravenous infusion. Golimumab is approved for the treatment of the adults with rheumatic diseases, and ulcerative colitis, Whereas in children, golimumab is indicated only for the treatment of active polyarticular juvenile idiopathic arthritis. We have written on the off-label use of subcutaneous golimumab, which helped to induce and maintain remission on a low-weight biologically experienced child with steroid-refractory ulcerative colitis flare.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 13-year-old pancolitis Syrian boy presented with abdominal pain and six to seven times bloody diarrhea. The child had treated with mesalamine 80\u200amg\/kg\/day, azathioprine 2.5\u200amg\/kg\/day, infliximab with an induction dose of 5\u200amg\/kg at weeks 0, 2, and 6 followed by 5\u200amg\/kg every 8\u200aweeks. Infliximab did not maintain remission as the patient suffered from two flares that required hospital admission, intravenous corticosteroids, and infliximab escalation. Initial tests disclosed leukocytosis, anemia, hypoalbuminemia, an elevation in C-reactive protein and fecal calprotectin. All Stool studies were negative including routine stool cultures, <jats:italic toggle=\"yes\">Clostridium difficile<\/jats:italic> toxin, <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic> O157:H7, Cryptosporidium, and microscopy for ova and parasites. A sigmoidoscopy revealed multiple large ulcerations and spontaneous bleeding, colon biopsies were negative for <jats:italic toggle=\"yes\">Clostridium difficile<\/jats:italic> and Cytomegalovirus. Cyclosporine, tacrolimus, and adalimumab were unavailable in Syria. Child's parents opposed colectomy as a treatment option.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Ulcerative colitis flare.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>A subcutaneous golimumab with a loading dose of 200\u200amg at week 0, followed by 100\u200amg at week 2, then 50\u200amg every 4 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient achieved clinical remission by week sixth and maintained the remission for the next 90\u200aweeks. At the time of last evaluation, tests, including C-reactive protein and fecal calprotectin, were within normal limits, complete colonoscopy revealed erythema, edema, mucosal friability, loss of vascular patterns, and pseudo-polyps. The Pediatric Ulcerative Colitis Activity Index and Mayo scores were 5 and 2 points, respectively. No adverse events were documented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Golimumab has shown potential efficacy and safety in the treatment of ulcerative colitis in children which may indicate a significant future role for subcutaneous golimumab in pediatrics ulcerative colitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027283","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:56:25Z","timestamp":1632502585000},"page":"e27283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-2096","authenticated-orcid":false,"given":"Marouf","family":"Alhalabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal Alaa","family":"Eddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Cheha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/00365529709000184","article-title":"Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort","volume":"32","author":"Langholz","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bpg.2004.01.002","article-title":"Specificities of inflammatory bowel disease in childhood","volume":"18","author":"Griffiths","year":"2004","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MPG.0b013e3182662233","article-title":"Management of pediatric ulcerative colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines","volume":"55","author":"Turner","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care\u2014an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/postgradmedj-2018-136072","article-title":"Optimal management of acute severe ulcerative colitis","volume":"95","author":"Jain","year":"2019","journal-title":"Postgrad Med J"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/acr.21788","article-title":"Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials","volume":"65","author":"Hsia","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3899\/jrheum.150712","article-title":"Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD Trial","volume":"43","author":"Keystone","year":"2016","journal-title":"J Rheumatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.22759","article-title":"Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial","volume":"68","author":"Emery","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/acr.23905","article-title":"Efficacy and safety of intravenous golimumab through one year in patients with active psoriatic arthritis","volume":"72","author":"Husni","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3899\/jrheum.180718","article-title":"Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: results through 1 year of the GO-ALIVE study","volume":"46","author":"Reveille","year":"2019","journal-title":"J Rheumatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"R17-20250504","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2036.2003.01540.x","article-title":"High-dose azathioprine in children with inflammatory bowel disease","volume":"17","author":"Fuentes","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s10620-015-3735-4","article-title":"Infliximab dose escalation as an effective strategy for managing secondary loss of response in ulcerative colitis","volume":"60","author":"Taxonera","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","article-title":"Assessing severity of disease in patients with ulcerative colitis","volume":"49","author":"Pabla","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1097\/MIB.0000000000001262","article-title":"Subcutaneous golimumab in pediatric ulcerative colitis: pharmacokinetics and clinical benefit","volume":"23","author":"Hyams","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"e000212","DOI":"10.1136\/bmjgast-2018-000212","article-title":"Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)","volume":"5","author":"Probert","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"key":"R26-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102529","article-title":"A Review on the use of anti-TNF in children and adolescents with inflammatory bowel disease","volume":"20","author":"Aardoom","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohn Colitis"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/gutjnl-2020-321185","article-title":"Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements)","volume":"69","author":"Chiu","year":"2020","journal-title":"Gut"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","article-title":"Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis","volume":"130","author":"Osterman","year":"2006","journal-title":"Gastroenterology"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","article-title":"Anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis: an update on safety","volume":"63","author":"Hyrich","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2011.04701.x","article-title":"Review article: defining remission in ulcerative colitis","volume":"34","author":"Travis","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20250504","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohn Colitis"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"e014581","DOI":"10.1136\/bmjopen-2016-014581","article-title":"Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis","volume":"7","author":"Freeman","year":"2017","journal-title":"BMJ Open"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"e19359","DOI":"10.1097\/MD.0000000000019359","article-title":"Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases","volume":"99","author":"Grinman","year":"2020","journal-title":"Medicine"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ecco-jcc\/jjv241","article-title":"Variability in golimumab exposure: a \u2018real-life\u2019 observational study in active ulcerative colitis","volume":"10","author":"Detrez","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R42-20250504","first-page":"01","article-title":"Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study","author":"Gehin","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","article-title":"Switching biologics in psoriasis\u2014practical guidance and evidence to support","volume":"13","author":"Tsai","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dth.12267","article-title":"An evolution in switching therapy for psoriasis patients who fail to meet treatment goals","volume":"28","author":"Kerdel","year":"2015","journal-title":"Dermatol Ther"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"otz033","DOI":"10.1093\/crocol\/otz033","article-title":"Reclassifying pseudopolyps in inflammatory bowel disease: histologic and endoscopic description in the new era of mucosal healing","volume":"1","author":"Rezapour","year":"2019","journal-title":"Crohns Colitis 360"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.14309\/00000434-201310001-01716","article-title":"Effects of immunomodulators on the pharmacokinetics and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: results from Phase 2\/3 PURSUIT-SC Induction and Maintenance Studies: 1716","volume":"108","author":"Adedokun","year":"2013","journal-title":"J Am Coll Gastroenterol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","article-title":"The benefit to risk balance of combining infliximab with azathioprine varies with age: A Markov Model","volume":"13","author":"Scott","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/gutjnl-2020-321269","article-title":"COVID-19 and immunomodulation in IBD","volume":"69","author":"Neurath","year":"2020","journal-title":"Gut"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.3748\/wjg.v26.i37.5534","article-title":"Review of inflammatory bowel disease and COVID-19","volume":"26","author":"Sultan","year":"2020","journal-title":"World J Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:13:18Z","timestamp":1746335598000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027283"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":49,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027283","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"2021-04-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}